Oncohema Key

Figure 45-1 Paul Ehrlich: birth of targeted therapy, 1911. For the next 40 years, great progress was made in developing additional chemotherapeutic anticancer agents. Two approaches were used. The first…

Figure 1-1 Relationship of carcinogenic to mutagenic potencies of chemical compounds The ability to quantify both the mutagenic potencies of a variety of chemical compounds, measured in the Ames mutagenesis…

AML, Acute myeloid leukemia. ∗ Determined among 1311 patients with de novo AML enrolled onto Study 8461 of the Cancer and Leukemia Group B. † Partial tandem duplication of the…

Figure 59-1 Immunohistochemistry (A) (1) An antibody specific for a particular protein, phosphate, sulfate, carbohydrate, or other moiety is allowed to bind to the tissue section. (2) A secondary “anti-antibody”…

Figure 7-1 Chemical structures of selected carcinogens. Causes of Cancer Epidemiology and Causal Criteria The landmark findings of Kennaway, Avery, Hershey, Chase, and others in the early part of the…

Figure 23-1 PCR and capillary sequencing of exons A generalized workflow is shown for the PCR-based amplification of specific exons in the human genome, their sequencing, and separation of the…

Figure 56-1 Hsp90 function is required for the establishment and maintenance of each of the eight hallmarks of cancer. Importantly, Hsp90 function is also critical for cancer cells to survive…

Figure 57-1 Actions of cytokine/growth factors binding to their receptors on the cell surface Cytokines and growth factors are the messengers that mediate intercellular communication. The regulation of cellular and…

Figure 48-1 The traditional “3 + 3” Phase I clinical trial design. The initial 3-patient cohort begins at a predefined dose. If no DLTs are observed, escalation to the next…

AML, Acute myeloid leukemia; BL, Burkitt’s lymphoma; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; ES, Ewing sarcoma. MicroRNAs were found to be involved in the pathophysiology of all…